Market Newsdesk

REDWOOD CITY, Calif., Nov. 20, 2020 /PRNewswire/ — Equinix, Inc. (Nasdaq: EQIX), the world’s digital infrastructure company, today announced that its executives will attend four upcoming investor conferences:

• Bank of America 2020 Global Data Center Virtual Conference on Wednesday, November 25. Jeremy Deutsch, President, Asia-Pacific, and Katrina Rymill, VP of Investor Relations & Sustainability, will present at 5:00 p.m. PST.

• 2020 Wells Fargo TMT Summit on Tuesday, December 1. Steve Madden, VP of Segment Marketing and Katrina Rymill, VP of Investor Relations & Sustainability, will present at 12:20 p.m. PST.

• NASDAQ 43rd Investor Conference on Wednesday, December 2. Keith Taylor, Chief Financial Officer, will present at 7:00 a.m. PST.

• Barclays 2020 Global Technology, Media and Telecommunications Virtual Conference on Thursday, December 10. Jon Lin, President, Americas, will present at 7:00 a.m. PST.

The presentations will be made available via webcast on the Investor Relations section of the Equinix website at www.equinix.com/investors.

About Equinix


Equinix
 (Nasdaq: EQIX) is the world’s digital infrastructure company, enabling digital leaders to harness a trusted platform to bring together and interconnect the foundational infrastructure that powers their success. Equinix enables today’s businesses to access all the right places, partners and possibilities they need to accelerate advantage. With Equinix, they can scale with agility, speed the launch of digital services, deliver world-class experiences and multiply their value.

 

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/media-alert-equinix-to-speak-at-upcoming-investor-conferences-301177942.html

SOURCE Equinix, Inc.

SANTA CLARITA, Calif., Nov. 20, 2020 /PRNewswire/ — In response to the U.S. Centers for Disease Control and Prevention (CDC) “Framework for Conditional Sailing Order” pertaining to resumption of U.S. cruise operations, Princess Cruises is extending its pause in global operations to allow time for the estimated preparation needed for completing required activities prior to sailing and taking into consideration the temporary seven-day cap on itineraries that call at a U.S. port. The cruise operations impacted include the following:

• All cruises sailing through March 31, 2021
• All cruises longer than seven days sailing in and out of United States ports through November 1, 2021

Additionally, due to the uncertainty about when international travel restrictions might be lifted, Princess Cruises is extending its pause in operations for cruises departing in and out of Japan through June 25, 2021.

“We are focused on preparing our ships to meet the CDC health and safety requirements for our eventual return to service,” said Jan Swartz, president of Princess Cruises. “We also appreciate the continued support we have received from our guests, partners and travel advisors, reinforcing for all of us why we do what we do.”

Guests currently booked on these cancelled voyages will have the option to receive a refundable Future Cruise Credit (FCC) equivalent to 100% of the cruise fare paid plus an additional non-refundable bonus FCC equal to 25% of the cruise fare.

To receive the above FCCs, no action is required by the guest or their travel advisor.

Alternatively, guests can request a full refund for all monies paid on their booking through this online form. Requests must be received by December 31, 2020 or guests will be registered for the Future Cruise Credit option.

Princess will protect travel advisor commissions on bookings for cancelled cruises that were paid in full in recognition of the critical role they play in the cruise line’s business and success.

The most current information and instructions for booked guests affected by these cancellations, and more information on FCCs and refunds, can be found online at Information on Impacted & Cancelled Cruises.

About Princess Cruises

:

One of the best-known names in cruising, Princess Cruises is an international premium cruise line and tour company operating a fleet of 15 modern cruise ships, carrying two million guests each year to 380 destinations around the globe, including the Caribbean, Alaska, Panama Canal, Mexican Riviera, Europe, South America, Australia/New Zealand, the South Pacific, Hawaii, Asia, Canada/New England, Antarctica and World Cruises. A team of professional destination experts have curated 170 itineraries, ranging in length from three to 111 days and Princess Cruises is continuously recognized as “Best Cruise Line for Itineraries.” In 2017 Princess Cruises, with parent company Carnival Corporation, introduced MedallionClass Vacations enabled by the OceanMedallion, the vacation industry’s most advanced wearable device, provided free to each guest sailing on a MedallionClass ship. The award-winning innovation offers the fastest way to an effortless personalized vacation giving guests more time to do the things they love most. The company is part of Carnival Corporation & plc (NYSE/LSE: CCL; NYSE:CUK).

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/princess-cruises-extends-pause-of-global-ship-operations-into-2021-301177874.html

SOURCE Princess Cruises

WENLING, China, Nov. 20, 2020 /PRNewswire/ — Fuling Global Inc. (Nasdaq: FORK) (“Fuling Global” or the “Company”), a manufacturer and distributor of mainly environmentally-friendly plastic and paper foodservice disposable products, announced that at an extraordinary general meeting of shareholders (the “EGM”) held today, the Company’s shareholders voted in favor of, among other things, the proposal to authorize and approve (i) the previously announced agreement and plan of merger dated as of September 1, 2020 (the “Merger Agreement”), by and among the Company, Fuling ParentCo Inc., an exempted company with limited liability incorporated under the laws of the Cayman Islands (“Parent”) and Fuling MergerCo Inc., an exempted company with limited liability incorporated under the laws of the Cayman Islands and a wholly-owned subsidiary of Parent (“Merger Sub”); (ii) the plan of merger required to be filed with the Registrar of Companies of the Cayman Islands (the “Plan of Merger”), pursuant to which Merger Sub will merge with and into the Company, with the Company continuing as the surviving company and becoming a wholly owned subsidiary of the Parent (the “Merger”); and (iii) any and all transactions contemplated by the Merger Agreement and the Plan of Merger, including the Merger.

Six registered shareholders entitled to vote were present at the EGM by proxy or by their duly authorized representatives representing 72.71% in nominal value of the total issued voting shares in the Company. As such, a quorum was present. The Merger Agreement, the Plan of Merger and the transactions contemplated thereby, including the Merger, were approved by approximately 95.25% of the ordinary shares present and voting in person or by proxy at the EGM.

The parties currently expect to complete the Merger as soon as practicable, subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement. Upon completion of the Merger, the Company will become a privately held company, and its ordinary shares will no longer be listed on the NASDAQ Capital Market.

About Fuling Global Inc.

Fuling Global manufactures and distributes mainly environmentally-friendly disposable serviceware for the foodservice industry, with six precision manufacturing facilities in the U.S., Mexico, Indonesia and China. The Company’s plastic and paper serviceware products include disposable cutlery, drinking straws, cups, plates and other plastic and paper products and are used by more than one hundred customers, including some of the world’s most notable quick-service restaurants and retailers, primarily in the U.S., China, Canada and European countries. More information about the Company can be found at: http://ir.fulingglobal.com/.

Safe Harbor Statement

This press release contains statements that express the Company’s current opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results and therefore are, or may be deemed to be, “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 (the “Act”). These forward-looking statements can be identified by terminology such as “if,” “will, “”expected” and similar statements. Forward-looking statements involve inherent risks, uncertainties and assumptions and other factors that could cause actual results to differ materially from those contained in any such statements. Risks, uncertainties and assumptions include, but are not limited to the following: uncertainties as to the expected benefits and costs of the proposed Merger, the expected timing of the completion of the Merger, and the parties’ ability to complete the Merger considering the various closing conditions; the possibility that financing may not be available; the possibility that various closing conditions for the transaction may not be satisfied or waived; and other risks and uncertainties discussed in documents filed with the SEC by the Company, as well as the Schedule 13E-3 transaction statement and the proxy statement filed by the Company. These forward-looking statements reflect the Company’s expectations as of the date of this press release. You should not rely upon these forward-looking statements as predictions of future events. The Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

View original content:http://www.prnewswire.com/news-releases/fuling-global-shareholders-approve-going-private-transaction-301177805.html

SOURCE Fuling Global Inc.

BOSTON, Nov. 20, 2020 /PRNewswire/ — Stealth BioTherapeutics Corp (Nasdaq: MITO) (“Stealth” or the “Company”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that it has entered into securities purchase agreements with several institutional investors to purchase 2,844,446 of its American Depositary Shares (“ADSs”), each ADS representing 12 ordinary shares of the Company, in a registered direct offering. The purchase price for one ADS is $1.125.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

The gross proceeds from this offering are expected to be approximately $3.2 million. This offering is expected to close on or about November 24, 2020, subject to the satisfaction of customary closing conditions.

The ADSs described above are being offered pursuant to a “shelf” registration statement (File No. 333-237542) filed with the Securities and Exchange Commission (SEC) and declared effective on April 10, 2020. The ADSs may be offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A prospectus supplement and the accompanying prospectus relating to the offering of the ADSs will be filed with the SEC. Electronic copies of the prospectus supplement and the accompanying prospectus relating to the offering of ADSs may be obtained, when available, on the SEC’s website at http://www.sec.gov or by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by e-mail: [email protected] or by telephone: (646) 975-6996.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

About Stealth

We are a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction. Mitochondria, found in nearly every cell in the body, are the body’s main source of energy production and are critical for normal organ function.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking include statements about the anticipated completion of the registered direct offering. Statements that are not historical facts, including statements about Stealth BioTherapeutics’ beliefs, plans and expectations, are forward-looking statements. The words “anticipate,” “expect,” “hope,” “plan,” “potential,” “possible,” “will,” “believe,” “estimate,” “intend,” “may,” “predict,” “project,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Stealth BioTherapeutics may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements as a result of known and unknown risks, uncertainties and other important factors, including: Stealth BioTherapeutics’ ability to obtain additional funding and to continue as a going concern; the impact of the COVID-19 pandemic; the ability to successfully demonstrate the efficacy and safety of Stealth BioTherapeutics’ product candidates and future product candidates; the preclinical and clinical results for Stealth BioTherapeutics’ product candidates, which may not support further development and marketing approval; the potential advantages of Stealth BioTherapeutics’ product candidates; the content and timing of decisions made by the U.S. FDA, the EMA or other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies, which may affect the initiation, timing and progress of preclinical studies and clinical trials of Stealth BioTherapeutics’ product candidates; Stealth BioTherapeutics’ ability to obtain and maintain requisite regulatory approvals and to enroll patients in its planned clinical trials; unplanned cash requirements and expenditures; competitive factors; Stealth BioTherapeutics’ ability to obtain, maintain and enforce patent and other intellectual property protection for any product candidates it is developing; and general economic and market conditions. These and other risks are described in greater detail under the caption “Risk Factors” included in the Stealth BioTherapeutics’ most recent Annual Report on Form 20-F filed with the SEC, as well as in any future filings with the SEC. Forward-looking statements represent management’s current expectations and are inherently uncertain. Except as required by law, Stealth BioTherapeutics does not undertake any obligation to update forward-looking statements made by us to reflect subsequent events or circumstances.

Investor Relations 

Stern Investor Relations
Janhavi Mohite, 212-362-1200
[email protected]

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/stealth-biotherapeutics-announces-3-2-million-registered-direct-offering-301177823.html

SOURCE Stealth BioTherapeutics Inc.

ST. LOUIS, Nov. 20, 2020 /PRNewswire/ — Centene Corporation (NYSE: CNC) will host its 2021 Financial Guidance and Investor Meeting, in a virtual format, on Friday, December 18^th, 2020. Michael F. Neidorff, Chairman, President and Chief Executive Officer, and Jeffrey A. Schwaneke, Executive Vice President and Chief Financial Officer, of Centene Corporation will host the virtual meeting, which will be streamed live on the Company’s website at www.centene.com, under the Investors section.

Additional details for the virtual meeting, as well as instructions for institutional investors and analysts to enable the Question & Answer component, to follow.

About Centene Corporation
Centene Corporation, a Fortune 50 company, is a leading multi-national healthcare enterprise that is committed to helping people live healthier lives. The Company takes a local approach – with local brands and local teams – to provide fully integrated, high-quality, and cost-effective services to government-sponsored and commercial healthcare programs, focusing on under-insured and uninsured individuals. Centene offers affordable and high-quality products to nearly 1 in 15 individuals across the nation, including Medicaid and Medicare members (including Medicare Prescription Drug Plans) as well as individuals and families served by the Health Insurance Marketplace, the TRICARE program, and individuals in correctional facilities. The Company also serves several international markets, and contracts with other healthcare and commercial organizations to provide a variety of specialty services focused on treating the whole person. Centene focuses on long-term growth and the development of its people, systems and capabilities so that it can better serve its members, providers, local communities, and government partners.

Centene uses its investor relations website to publish important information about the company, including information that may be deemed material to investors. Financial and other information about Centene is routinely posted and is accessible on Centene’s investor relations website, http://www.centene.com/investors.           

 

View original content:http://www.prnewswire.com/news-releases/centene-corporation-to-host-virtual-2021-financial-guidance-and-investor-meeting-on-december-18-2020-301177916.html

SOURCE Centene Corporation

NEW YORK, Nov. 20, 2020 /PRNewswire/ — AIkido Pharma Inc. (the “Company” or “AIkido”) (NASDAQ: AIKI) today announced the results from the virtual 2020 Annual Meeting of Stockholders (the “Meeting”) held on November 17, 2020 (the “Meeting”).

All proposals that were presented to the stockholders were approved at the Meeting, except for the proposal to amend the Company’s Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split of the Company’s common stock (the “Common Stock”) at a ratio of up to one-for-ten (the “Amendment Proposal”). Accordingly, the Company adjourned the Meeting to allow more time for stockholders to consider the Amendment Proposal.  The adjournment of the Meeting will preserve the September 24, 2020 record date for the determination of stockholders entitled to receive notice of and vote at the upcoming adjourned meeting to be held at 12:00 p.m. on December 4, 2020.

The detailed voting results for the Meeting are provided in the Company’s Current Report on Form 8-K, filed with the U.S. Securities and Exchange Commission (the “SEC”) on November 20, 2020.

The Company urges all stockholders who have not yet voted to vote in favor of the Amendment Proposal. Approval of the Amendment Proposal and the resulting reverse stock split is critical.  The primary objective of the reverse stock split is to raise the per share trading price of the Common Stock to comply with the Nasdaq minimum share price listing rule to allow the Company to continue to list on Nasdaq.  The higher stock price resulting from the reverse stock split and the listing of the Common Stock on Nasdaq is important for the marketability of the Common Stock to the financial community and investing public.  If the reverse stock split is not effectuated, it could limit the number of potential buyers of the Common Stock as many institutional investors have policies prohibiting them from holding lower-priced stocks in their portfolios.  Also, brokerage houses frequently have internal practices and policies that discourage individual brokers from dealing in lower-priced stocks.  Top proxy advisory firms ISS and Glass Lewis, who together provide voting recommendations on stockholder meetings to a majority of institutional stockholders, both recommend a “FOR” vote for this proposal in order to maintain listing on Nasdaq.

We urge you to please vote your shares of AIkido today.  You may do so by contacting MacKenzie Partners at 1-800-322-2885 (toll-free in the U.S.) or 212-929-5500.

MacKenzie Partners can also take your vote via email. To vote by email, simply send an email with your voting instructions to [email protected] . A sample email is below:

To:  [email protected]

Cc:  [email protected]: 

Re:  AIkido Pharma Inc. Annual Meeting

Dear Mr. Jaegers;

Please vote my shares of AIkido Pharma Inc. Common Stock for the 2020 Annual Meeting of Stockholders as follows:

1. FOR the amendment to effect reverse stock split

Proposals 2, 3a,3b,3c,3d, 3e, 3f, 4, 5, and 6 will be voted FOR in order to complete the proxy.  Please be advised that these proposals have already passed at the shareholder meeting on November 17, 2020.

The shares are registered in the name of ___________

Thank you

Your vote is very important, regardless of the number of shares you own. Please take a moment to vote your shares by contacting MacKenzie Partners today.

Thank you for your support.

Important Information and Where to Find It
This communication may be deemed to be solicitation material in respect to the Meeting and the Proposals. On October 5, 2020, the Company initially filed the Definitive Proxy Statement with the SEC. The Company gave notice and mailed the Definitive Proxy Statement to certain stockholders on or about October 5, 2020. The Company may file other documents with the SEC in connection with the Meeting. BEFORE MAKING ANY VOTING DECISION, STOCKHOLDERS ARE URGED TO READ THESE MATERIALS CAREFULLY AND, IN THEIR ENTIRETY, BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY. Stockholders may obtain, free of charge, copies of the Definitive Proxy Statement and any other documents filed by the Company with the SEC in connection with the Meeting at the SEC’s website (http://www.sec.gov) and on the investor relations section of the Company’s website at www.aikidopharma.com. Investors and stockholders are urged to read the Definitive Proxy Statement and the other relevant materials before making any voting decision with respect to the Meeting and the Proposals.

Non-Solicitation
This communication does not constitute an offer to sell or solicitation of an offer to buy any securities, nor will there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

Participants in the Solicitation
The Company and its directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of the Company in connection with the Meeting. Additional information regarding the directors and executive officers of the Company is included in the Company’s Definitive Proxy Statement relating to the Meeting, filed with the SEC on October 5, 2020. These documents are available free of charge from the sources indicated above.

About AIkido Pharma Inc.
AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics.  The Company’s platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In addition, we are constantly seeking to grow our pipeline to treat unmet medical needs in oncology.  The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company’s filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Contact:

Investor Relations:      

Hayden IR
Brett Maas, Managing Partner
Phone: (646) 536-7331
Email: [email protected]
www.haydenir.com

AIkido Pharma Inc.:   

Phone: 212-745-1373
Email: [email protected]
www.aikidopharma.com

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/aikido-pharma-inc-announces-results-of-2020-annual-stockholder-meeting-301177934.html

SOURCE AIkido Pharma Inc.

SEATTLE, Nov. 20, 2020 /PRNewswire/ — A market defined by intense demand for relatively tight supply pushed month-over-month and quarterly home value growth to levels not seen since 2005, according to Zillow’s® latest Real Estate Market Report^[1]. Rent appreciation, meanwhile, is steaming ahead in many Midwest and Sun Belt cities while declining in major coastal metros.

The high-demand market also meant more homes changed hands than at any time in the past 15 years. October’s seasonally adjusted annualized rate (SAAR) of home sales was 6.85 million, according to the National Association of Realtors, which was the strongest pace since 2005. Zillow economists expect this rate to remain elevated for the coming year. It is forecasted to average 6.42 million through September 2021, which would mark the strongest year for home sales since 2006.

Home value growth accelerated from 0.9% month over month growth in September to 1% in October, the fastest rate in 15 years. That growth has only been higher — barely — on four occasions in the 24-year history of the Zillow Home Value Index: in June, July, August, and September of 2005. Typical home values now stand at $262,604.

“The red-hot housing market of this summer and fall is now clearly reflected in soaring home value appreciation,”  said Zillow senior economist Jeff Tucker. “We haven’t seen such steep, short-term appreciation since the summer of 2005, but this time it is driven by buyers with strong credit and incomes securing affordable fixed-rate mortgages, unlike the wave of poorly-vetted, exotic mortgages that financed the last boom. The simple fact is that millions of well-qualified Millennials are seriously shopping for houses and they are competing for a shortfall of homes for sale.”

In September, quarterly growth for home values reached 2.3%, then the largest increase since the summer of 2013, when the U.S. was recovering from the Great Recession. In October, quarterly growth reached 2.6%, the highest since November 2005. Home values rose 6.6% year over year last October the annual growth rate was 3.9%.

No major metro area witnessed a drop in home values from September to October. Monthly value increases ranged from 0.6% in Richmond, Va., to 1.9% in San Jose. Growth accelerated in 34 of the top 50 markets, was flat in 13, and decelerated in 3: Las Vegas, Los Angeles, and Riverside.

Strength in the for-sale market has coincided with continuing weakness in the rental market. Rent prices dropped by 0.1% from September to October to $1,751. Nationwide, typical rents are up just under 0.9% compared to October 2019. Annual growth was 3.4% in October 2019.

Yearly rent declines deepened in October in former bastions of growth, including New York (-8.1%), San Francisco (-6.9%), Boston (-5%) and San Jose (-4.2%). These cities also exhibited significant month-over-month declines in rent, along with Seattle (-1.7%), Chicago (-0.9%), and Washington, DC (-0.9%).  

Momentum in the rental market still favors Sun Belt and Midwestern cities. Among the 50 largest U.S. metros, leaders in rent growth since September were Providence, Rhode Island (2.2%), Phoenix (1.6%), Las Vegas (1.4%) and Riverside (1.3%). Year over year growth has been highest in Memphis (9.5%), Phoenix (8.2%), Riverside (8.1%), and Providence (7.5%).

Market stats from the week ending Nov. 14 show pending sales slowing late in the season, dropping 3.6% week over week, but still up a substantial 14.5% compared to 2019. Although new listings are coming online faster than they usually do in November, the decline of available inventory that began in early June continued, dropping 1.5% since the previous week to 33.3% below last year’s stock.

Mortgage rates listed by third-party lenders on Zillow started the month at 2.94%, rose to 3.00% on Oct. 21, then fell to 2.76% on Oct. 27 before finishing out the month at 2.79%. Zillow’s real-time mortgage rates are based on thousands of custom mortgage quotes submitted daily to anonymous borrowers on the Zillow Group Mortgages site by third-party lenders and reflect recent changes in the market^[2].

About Zillow
Zillow, the most visited real estate website in the U.S., is building an on-demand real estate experience. Whether selling, buying, renting or financing, customers can turn to Zillow’s businesses to find and get into their next home with speed, certainty and ease.

In addition to for-sale and rental listings, Zillow Offers buys and sells homes directly in dozens of markets across the country, allowing sellers control over their timeline. Zillow Home Loans, our affiliate lender, provides our customers with an easy option to get pre-approved and secure financing for their next home purchase.

Millions of people visit Zillow Group sites every month to start their home search, and now they can rely on Zillow to help them finish it — with the same confidence, ease and empowerment they’ve come to expect from real estate’s most trusted brand.

Zillow is owned and operated by Zillow Group, Inc. (NASDAQ:Z and ZG).  

^[1]
 The Zillow Real Estate Market Reports are a monthly overview of the national and local real estate markets. The reports are compiled by Zillow Real Estate Research. For more information, visit www.zillow.com/research/. The data in Zillow’s Real Estate Market Reports are aggregated from public sources by a number of data providers for 928 metropolitan and micropolitan areas dating back to 1996. Mortgage and home loan data are typically recorded in each county and publicly available through a county recorder’s office. Methodologies and all current monthly data at the national, state, metro, city, ZIP code and neighborhood level can be accessed at www.zillow.com/research/data.

^[2]
 Zillow Group Marketplace, Inc. is a licensed mortgage broker, NMLS #1303160.

 

View original content:http://www.prnewswire.com/news-releases/home-values-rising-faster-than-at-any-time-since-2005-301177914.html

SOURCE Zillow